Why did Ansell (ASX:ANN) CFO Brian Montgomery resign?

Brian Montgomery resigned to accept the Chief Financial Officer position at Hologic, a large US-based medical technology company. His departure follows a period at Ansell defined by significant strategic transformation and strengthened financial discipline.

Who is replacing Brian Montgomery as CFO at Ansell (ASX:ANN)?

Fred Marx has been appointed as the Acting CFO, effective immediately, while the company searches for a permanent replacement. Marx is a company insider currently serving as Vice President of Corporate FP&A, Strategy, and Transformation.

How might the resignation of the CFO affect the Ansell (ASX:ANN) share price?

The share price was $27.50 at the time of the announcement, and executive departures can sometimes trigger short-term volatility due to uncertainty. However, because the company immediately appointed an experienced interim successor and cited a clear reason for the exit (a new role at Hologic), the market may view this as an orderly transition.

Does this executive change signal a shift in Ansell’s long-term strategy?

There is no indication of a strategy pivot; CEO Nathalie Ahlström specifically credited Montgomery with strengthening the company's current strategic direction. The appointment of Fred Marx, who currently leads Strategy and Transformation, suggests that Ansell intends to maintain its existing roadmap.

What are the key risks for Ansell (ASX:ANN) shareholders during this transition?

The primary risk is "key person risk" and the potential for a prolonged search for a permanent CFO, which can distract senior management. While Fred Marx is experienced, an interim leadership phase can sometimes lead to a "wait and see" approach regarding major capital allocation decisions.

ASX-listed Ansell CFO Brian Montgomery resigns

Ansell CFO Brian Montgomery resigns

Written by Liezl GambePublished Apr. 16 2026Last Updated Apr. 16 2026

Ansell (ASX:ANN) announced the resignation of its CFO, Brian Montgomery.

After a tenure marked by strategic transformation, Montgomery is set to depart the company to assume the CFO role at Hologic, a US-based medical technology firm recently valued at approximately US$18 billion following its acquisition.

Ansell has initiated a formal search process with a professional recruitment firm to identify a permanent successor.

To ensure organisational stability during this period, Fred Marx has been appointed as acting CFO, effective immediately.

Marx is currently the Vice President of Corporate FP&A, strategy, and transformation at Ansell and brings over two decades of senior leadership expertise to the position.

His extensive history with the company includes pivotal roles such as Vice President of finance for global operations and supply chain and finance director for the Americas and medical division.

Marx has navigated the company through a previous CFO transition in an acting capacity.

Nathalie Ahlström, Managing Director and CEO of Ansell, expressed her gratitude for Montgomery’s contributions, highlighting his role in strengthening the company’s financial discipline and strategic direction.

Ahlström noted that while the board completes the global search for a permanent replacement, she remains confident in the leadership provided by Marx.

At the time of reporting, Ansell’s share price was $27.50.